O	0	9	Competing
O	10	16	causes
O	17	19	of
O	20	25	death
O	26	30	from
O	31	32	a
O	33	43	randomized
O	44	49	trial
O	50	52	of
O	53	61	extended
B-intervention	62	70	adjuvant
I-intervention	71	80	endocrine
I-intervention	81	88	therapy
O	89	92	for
O	93	99	breast
O	100	106	cancer
O	106	107	.

O	108	113	Older
O	114	119	women
O	120	124	with
O	125	130	early
O	130	131	-
O	131	136	stage
O	137	143	breast
O	144	150	cancer
O	151	161	experience
O	162	168	higher
O	169	174	rates
O	175	177	of
O	178	181	non
O	181	182	-
O	182	188	breast
O	189	195	cancer
O	195	196	-
O	196	203	related
O	204	209	death
O	209	210	.

O	211	213	We
O	214	222	examined
O	223	230	factors
O	231	241	associated
O	242	246	with
O	247	252	cause
O	252	253	-
O	253	261	specific
O	262	267	death
O	268	270	in
O	271	272	a
O	273	278	large
O	279	285	cohort
O	286	288	of
O	289	295	breast
O	296	302	cancer
O	303	311	patients
O	312	319	treated
O	320	324	with
O	325	333	extended
O	334	342	adjuvant
O	343	352	endocrine
O	353	360	therapy
O	360	361	.

O	362	364	In
O	365	368	the
O	369	371	MA
O	371	372	.
O	372	374	17
O	375	380	trial
O	380	381	,
O	382	391	conducted
O	392	394	by
O	395	398	the
O	399	407	National
O	408	414	Cancer
O	415	424	Institute
O	425	427	of
B-location	428	434	Canada
O	435	443	Clinical
O	444	450	Trials
O	451	456	Group
O	456	457	,
B-total-participants	458	462	5170
O	463	469	breast
O	470	476	cancer
O	477	485	patients
O	486	487	(
O	487	493	median
O	494	497	age
O	498	499	=
B-age	500	502	62
O	503	508	years
O	508	509	;
O	510	515	range
O	516	517	=
O	518	520	32
O	520	521	-
O	521	523	94
O	524	529	years
O	529	530	)
B-eligibility	531	534	who
I-eligibility	535	539	were
I-eligibility	540	547	disease
I-eligibility	548	552	free
I-eligibility	553	558	after
I-eligibility	559	572	approximately
I-eligibility	573	574	5
I-eligibility	575	580	years
I-eligibility	581	583	of
I-eligibility	584	592	adjuvant
I-eligibility	593	602	tamoxifen
I-eligibility	603	612	treatment
O	613	617	were
O	618	626	randomly
O	627	635	assigned
O	636	638	to
O	639	648	treatment
O	649	653	with
O	654	663	letrozole
O	664	665	(
B-intervention-participants	665	669	2583
O	670	675	women
O	675	676	)
O	677	679	or
B-control	680	687	placebo
O	688	689	(
B-control-participants	689	693	2587
O	694	699	women
O	699	700	)
O	700	701	.

O	702	705	The
O	706	712	median
O	713	719	follow
O	719	720	-
O	720	722	up
O	723	726	was
O	727	728	3
O	728	729	.
O	729	730	9
O	731	736	years
O	737	738	(
O	738	743	range
O	744	745	0
O	745	746	-
O	746	747	7
O	748	753	years
O	753	754	)
O	754	755	.

O	756	758	We
O	759	771	investigated
O	772	775	the
O	776	787	association
O	788	790	of
O	791	793	11
O	794	802	baseline
O	803	810	factors
O	811	815	with
O	816	819	the
O	820	829	competing
O	830	835	risks
O	836	838	of
O	839	844	death
O	845	849	from
O	850	856	breast
O	857	863	cancer
O	863	864	,
O	865	870	other
O	871	883	malignancies
O	883	884	,
O	885	888	and
O	889	894	other
O	895	901	causes
O	901	902	.

O	903	906	All
O	907	918	statistical
O	919	924	tests
O	925	929	were
O	930	933	two
O	933	934	-
O	934	939	sided
O	940	950	likelihood
O	951	956	ratio
O	957	966	criterion
O	967	972	tests
O	972	973	.

O	974	980	During
O	981	987	follow
O	987	988	-
O	988	990	up
O	990	991	,
O	992	995	256
B-outcome	996	1002	deaths
O	1003	1007	were
O	1008	1016	reported
O	1017	1018	(
O	1018	1021	102
O	1022	1026	from
O	1027	1033	breast
O	1034	1040	cancer
O	1040	1041	,
O	1042	1044	50
O	1045	1049	from
O	1050	1055	other
O	1056	1068	malignancies
O	1068	1069	,
O	1070	1073	100
O	1074	1078	from
O	1079	1084	other
O	1085	1091	causes
O	1091	1092	,
O	1093	1096	and
O	1097	1101	four
O	1102	1106	from
O	1107	1109	an
O	1110	1117	unknown
O	1118	1123	cause
O	1123	1124	)
O	1124	1125	.

B-outcome	1126	1129	Non
I-outcome	1129	1130	-
I-outcome	1130	1136	breast
I-outcome	1137	1143	cancer
I-outcome	1144	1150	deaths
O	1151	1160	accounted
O	1161	1164	for
O	1165	1167	60
O	1167	1168	%
O	1169	1171	of
O	1172	1175	the
O	1176	1179	252
O	1180	1185	known
O	1186	1192	deaths
O	1193	1194	(
O	1194	1196	72
O	1196	1197	%
O	1198	1201	for
O	1202	1207	those
O	1208	1209	>
O	1210	1212	or
O	1213	1214	=
O	1215	1217	70
O	1218	1223	years
O	1224	1227	and
O	1228	1230	48
O	1230	1231	%
O	1232	1235	for
O	1236	1241	those
O	1242	1243	<
O	1244	1246	70
O	1247	1252	years
O	1252	1253	)
O	1253	1254	.

O	1255	1258	Two
O	1259	1267	baseline
O	1268	1275	factors
O	1276	1280	were
O	1281	1295	differentially
O	1296	1306	associated
O	1307	1311	with
O	1312	1316	type
O	1317	1319	of
O	1320	1325	death
O	1325	1326	:
B-outcome	1327	1341	cardiovascular
I-outcome	1342	1349	disease
O	1350	1353	was
O	1354	1364	associated
O	1365	1369	with
O	1370	1371	a
O	1372	1385	statistically
O	1386	1397	significant
O	1398	1407	increased
O	1408	1412	risk
O	1413	1415	of
O	1416	1421	death
O	1422	1426	from
O	1427	1432	other
O	1433	1439	causes
O	1440	1441	(
O	1441	1442	P
O	1442	1443	.
O	1443	1446	002
O	1446	1447	)
O	1447	1448	,
O	1449	1452	and
B-outcome	1453	1465	osteoporosis
O	1466	1469	was
O	1470	1480	associated
O	1481	1485	with
O	1486	1487	a
O	1488	1501	statistically
O	1502	1513	significant
O	1514	1523	increased
O	1524	1528	risk
O	1529	1531	of
O	1532	1537	death
O	1538	1542	from
O	1543	1548	other
O	1549	1561	malignancies
O	1562	1563	(
O	1563	1564	P
O	1564	1565	.
O	1565	1567	05
O	1567	1568	)
O	1568	1569	.

O	1570	1572	An
O	1573	1582	increased
B-outcome	1583	1587	risk
I-outcome	1588	1590	of
I-outcome	1591	1597	breast
I-outcome	1598	1604	cancer
I-outcome	1604	1605	-
I-outcome	1605	1613	specific
I-outcome	1614	1619	death
O	1620	1623	was
O	1624	1634	associated
O	1635	1639	with
O	1640	1645	lymph
O	1646	1650	node
O	1651	1662	involvement
O	1663	1664	(
O	1664	1665	P
O	1666	1667	<
O	1668	1669	.
O	1669	1672	001
O	1672	1673	)
O	1673	1674	.

O	1675	1684	Increased
O	1685	1689	risk
O	1690	1692	of
O	1693	1698	death
O	1699	1703	from
O	1704	1707	all
O	1708	1713	three
O	1714	1720	causes
O	1721	1724	was
O	1725	1735	associated
O	1736	1740	with
O	1741	1746	older
O	1747	1750	age
O	1751	1752	(
O	1752	1753	P
O	1754	1755	<
O	1756	1757	.
O	1757	1760	001
O	1760	1761	)
O	1761	1762	.

O	1763	1766	Non
O	1766	1767	-
O	1767	1773	breast
O	1774	1780	cancer
O	1780	1781	-
O	1781	1788	related
O	1789	1795	deaths
O	1796	1800	were
O	1801	1805	more
O	1806	1812	common
O	1813	1817	than
O	1818	1824	breast
O	1825	1831	cancer
O	1831	1832	-
O	1832	1840	specific
O	1841	1847	deaths
O	1848	1850	in
O	1851	1855	this
O	1856	1862	cohort
O	1863	1865	of
O	1866	1867	5
O	1867	1868	-
O	1868	1872	year
O	1873	1879	breast
O	1880	1886	cancer
O	1887	1896	survivors
O	1896	1897	,
O	1898	1908	especially
O	1909	1914	among
O	1915	1920	older
O	1921	1926	women
O	1926	1927	.
